Background and Scope of the Review
The Queensland Government commissioned an independent review into the use of puberty blockers (Stage 1) and cross-sex hormones (Stage 2) for children and adolescents within the Queensland public health system.
The scope of the review extended beyond narrow clinical questions. It examined:
- The quality and strength of the medical evidence
- Short-, medium-, and long-term risks and benefits
- Clinical governance and safeguarding arrangements
- Ethical and legal considerations, including consent and decision-making capacity
- Whether current practices meet standards of evidence-based, child-centred healthcare
The review was therefore not an ideological exercise, but a comprehensive assessment of whether the medicalisation of gender-distressed minors is justified, safe, and consistent with accepted standards of care.
Key Findings (Chapters 4 and 5)
1. Weak and Uncertain Evidence Base
The review found that the evidence supporting puberty blockers and cross-sex hormones for minors is low quality, largely observational, and lacks long-term follow-up data.
There is:
- No robust evidence demonstrating sustained mental health benefits
- Insufficient data on long-term outcomes for bone density, fertility, sexual function, and neurological development
- Ongoing uncertainty about whether benefits outweigh risks
Claims that these interventions are “fully reversible” or well-established were not supported by the evidence reviewed.
2. Mental Health Outcomes Are Not Well Established
The review noted that many children presenting with gender distress also experience:
- Autism spectrum conditions
- Anxiety and depression
- Trauma, psychosocial stressors, or family instability
The assumption that medical transition reliably resolves distress or reduces suicidality was not strongly supported. In many cases, gender distress may be one expression of broader psychological vulnerability requiring careful, individualised therapeutic support.
3. Safeguarding and Clinical Practice Concerns
Significant concerns were raised about:
- Inconsistent assessment processes
- Limited documentation of alternative treatment pathways
- A clinical culture in which “affirmation” had become the default response
The review emphasised the need for greater caution, stronger governance, and a return to genuinely exploratory, multidisciplinary care.
4. Ethical and Legal Complexity
The review acknowledged unresolved ethical questions about:
- Whether children can meaningfully consent to interventions with permanent or life-altering consequences
- How to balance a child’s expressed distress against their long-term welfare
- The risk of premature medicalisation during normal developmental uncertainty
Rather than endorsing routine medical intervention, the review supported a more precautionary approach.
Overall Conclusions of the Review
Taken as a whole, the Queensland Hormone Treatment Review does not provide a strong evidentiary basis for the routine use of puberty blockers or cross-sex hormones in minors within the public health system.
It supports:
- A cautious, evidence-led approach
- Stronger safeguards
- Prioritisation of non-invasive, psychological, and family-based support
- Ongoing review as higher-quality evidence becomes available
Consistency with the UN Convention on the Rights of the Child
The Queensland Government has chosen to continue restrictions on puberty blockers for minors. From the standpoint of the UN Convention on the Rights of the Child (CRC), this decision is defensible and justified.
Best Interests of the Child (Article 3)
The CRC requires that the child’s best interests be a primary consideration. Where medical interventions involve:
- Irreversible or poorly understood effects
- Significant uncertainty of benefit
- Potential lifelong consequences
a precautionary pause is consistent with protecting children from harm.
Right to Life, Survival, and Development (Article 6)
Children have the right to healthy physical, psychological, and social development. Interventions that interrupt normal puberty and may compromise fertility or sexual development raise legitimate concerns under this article.
Delaying medical intervention while prioritising supportive care respects this right.
Right to Be Heard (Article 12)
While children’s views must be taken seriously, the CRC does not require states to grant children autonomous consent to experimental or irreversible medical treatments.
Listening to a child does not obligate the state to provide interventions where risks are substantial and evidence is weak.
Right to the Highest Attainable Standard of Health (Article 24)
This right refers to safe, effective, and evidence-based healthcare. The review found that puberty blockers for minors do not yet meet this threshold.
Providing psychological care and safeguarding children from uncertain medical harm aligns with Article 24.
Our Conclusion
Women Speak Tasmania considers that the findings of the Queensland Hormone Treatment Review support a child-centred, rights-respecting approach.
Continuing restrictions on puberty blockers for minors:
- Aligns with the best interests of the child
- Reflects the precautionary principle where evidence is uncertain
- Protects children’s right to healthy development
- Upholds international child-rights obligations under the CRC
This approach does not deny care to distressed children. Rather, it prioritises:
- Psychological support
- Family involvement
- Careful assessment
- Protection from premature and potentially harmful medicalisation
Children deserve compassion, support, and honesty — not medical interventions that outpace the evidence.
Sources:
Queensland Independent Review Advice Report. 2025 – https://www.health.qld.gov.au/__data/assets/pdf_file/0035/1478843/Queensland-Hormone-Treatment-Review-Report-and-Annexures.pdf
Convention on the Rights of the Child. United Nations. 1989. – https://www.ohchr.org/en/instruments-mechanisms/instruments/convention-rights-child